These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10052325)

  • 1. Rational financing.
    Birndorf HC
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE33-4. PubMed ID: 10052325
    [No Abstract]   [Full Text] [Related]  

  • 2. Financing biotechnology in an inefficient market.
    Purcell DJ
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE31-2. PubMed ID: 10052324
    [No Abstract]   [Full Text] [Related]  

  • 3. Financing flees in Q3.
    Lawrence S
    Nat Biotechnol; 2006 Nov; 24(11):1312. PubMed ID: 17093463
    [No Abstract]   [Full Text] [Related]  

  • 4. Europe needs a single, deep capital market.
    Hodgson J
    Nat Biotechnol; 2002 Oct; 20(10):960-1. PubMed ID: 12355101
    [No Abstract]   [Full Text] [Related]  

  • 5. Writing your business plan.
    Cohen L
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE33-5. PubMed ID: 12089584
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotech finance: a family affair.
    Hurwitz EM
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE35-7. PubMed ID: 10052326
    [No Abstract]   [Full Text] [Related]  

  • 7. Picking your VC.
    Greene HE
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE25-6. PubMed ID: 10052321
    [No Abstract]   [Full Text] [Related]  

  • 8. Strategic consolidation: the biotechnology business model for the 21st century.
    Esposito RS; Ostro MJ
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE16-7. PubMed ID: 10052317
    [No Abstract]   [Full Text] [Related]  

  • 9. Companies struggle amid stock market gloom.
    Mitchell P
    Nat Biotechnol; 2002 Oct; 20(10):961-2. PubMed ID: 12355102
    [No Abstract]   [Full Text] [Related]  

  • 10. Public markets show signs of life.
    Mitchell P
    Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181
    [No Abstract]   [Full Text] [Related]  

  • 11. The hermit crab solution.
    Silverman E
    Nat Biotechnol; 2006 Mar; 24(3):245-7. PubMed ID: 16680810
    [No Abstract]   [Full Text] [Related]  

  • 12. Diversify to multiply.
    Jacobs T
    Nat Biotechnol; 2005 Apr; 23(4):419. PubMed ID: 15815663
    [No Abstract]   [Full Text] [Related]  

  • 13. Intellectual property as a foundation for funding.
    Meltzer SL; Marks MS; McCormick JT
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE47-50. PubMed ID: 12089588
    [No Abstract]   [Full Text] [Related]  

  • 14. At ground level.
    Bertschinger J
    Nat Biotechnol; 2010 Aug; 28(8):775-7. PubMed ID: 20722095
    [No Abstract]   [Full Text] [Related]  

  • 15. European markets target foreign biotechs.
    Louët S
    Nat Biotechnol; 2003 Jul; 21(7):719. PubMed ID: 12833075
    [No Abstract]   [Full Text] [Related]  

  • 16. The future of biotechnology funding: An interview with venture capitalist Dennis Purcell. Interviewed by Elaine Musgrave.
    Purcell D
    Clin Transl Sci; 2009 Oct; 2(5):320-1. PubMed ID: 20443914
    [No Abstract]   [Full Text] [Related]  

  • 17. Valuing biotechnology assets.
    Nelson TR; Mukherji A
    Nat Biotechnol; 1998 Jun; 16(6):525-9. PubMed ID: 9624681
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotech equities heat up in 1Q12.
    Yang W
    Nat Biotechnol; 2012 May; 30(5):384. PubMed ID: 22565955
    [No Abstract]   [Full Text] [Related]  

  • 19. Putting a price on biotechnology.
    Stewart JJ; Allison PN; Johnson RS
    Nat Biotechnol; 2001 Sep; 19(9):813-7. PubMed ID: 11533634
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategic rethink for German biotechnology.
    Fernandes M; Miska D
    Nat Biotechnol; 2002 Oct; 20(10):970-1. PubMed ID: 12355106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.